Similar articles for PMID: 31847644

Year	Number of Results
1999	1
2000	4
2003	1
2005	2
2006	2
2007	2
2008	5
2009	1
2012	9
2013	10
2014	9
2015	11
2016	14
2017	8
2018	10
2019	8
2020	6
2021	7
2022	4
2024	0

1

Once daily combined inhaled steroid and ultra long-acting bronchodilator prescribing in pediatric asthma: a dual Center retrospective cohort study.

Langley RJ, Dryden C, Westwood J, Anderson E, Thompson A, Urquhart D. Langley RJ, et al. J Asthma. 2021 Apr;58(4):512-513. doi: 10.1080/02770903.2019.1702674. Epub 2019 Dec 17. J Asthma. 2021. PMID: 31847644

2

Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.

Wolthers OD. Wolthers OD. Recent Pat Inflamm Allergy Drug Discov. 2015;9(2):144-50. doi: 10.2174/1872213x10666151119144907. Recent Pat Inflamm Allergy Drug Discov. 2015. PMID: 26581314 Review.

3

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.

Albertson TE, Richards JR, Zeki AA. Albertson TE, et al. Ther Adv Respir Dis. 2016 Feb;10(1):43-56. doi: 10.1177/1753465815619136. Epub 2015 Dec 14. Ther Adv Respir Dis. 2016. PMID: 26668137 Free PMC article. Review.

4

Assessment of Adherence and Asthma Medication Ratio for a Once-Daily and Twice-Daily Inhaled Corticosteroid/Long-Acting β-Agonist for Asthma.

Stanford RH, Averell C, Parker ED, Blauer-Peterson C, Reinsch TK, Buikema AR. Stanford RH, et al. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1488-1496.e7. doi: 10.1016/j.jaip.2018.12.021. Epub 2019 Jan 10. J Allergy Clin Immunol Pract. 2019. PMID: 30639604

5

Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β₂-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial.

Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin JM. Devillier P, et al. Respir Med. 2018 Aug;141:111-120. doi: 10.1016/j.rmed.2018.06.009. Epub 2018 Jun 9. Respir Med. 2018. PMID: 30053956 Free article. Clinical Trial.

6

Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.

Bernstein D, Andersen L, Forth R, Jacques L, Yates L. Bernstein D, et al. J Asthma. 2018 Sep;55(9):984-993. doi: 10.1080/02770903.2017.1386214. Epub 2018 Apr 13. J Asthma. 2018. PMID: 28961020 Clinical Trial.

7

Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.

Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, Nunn C, O'Byrne PM. Bernstein DI, et al. J Asthma. 2015;52(10):1073-83. doi: 10.3109/02770903.2015.1056350. Epub 2015 Aug 18. J Asthma. 2015. PMID: 26291137 Clinical Trial.

8

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.

Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID. Lee LA, et al. Lancet Respir Med. 2021 Jan;9(1):69-84. doi: 10.1016/S2213-2600(20)30389-1. Epub 2020 Sep 9. Lancet Respir Med. 2021. PMID: 32918892 Clinical Trial.

9

Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.

Hozawa S, Terada M, Haruta Y, Hozawa M. Hozawa S, et al. Pulm Pharmacol Ther. 2016 Apr;37:15-23. doi: 10.1016/j.pupt.2016.01.005. Epub 2016 Feb 2. Pulm Pharmacol Ther. 2016. PMID: 26850307 Clinical Trial.

10

Adherence and usage patterns of inhaled corticosteroids-long-acting beta-agonists by using inhaler-monitoring technology.

Stanford RH, Averell CM, Johnson PT, Buysman EK, Carlyle MH. Stanford RH, et al. Allergy Asthma Proc. 2020 Jul 1;41(4):256-264. doi: 10.2500/aap.2020.41.200037. Allergy Asthma Proc. 2020. PMID: 32605696

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

93 results

Results by year